Lingling Li

Lingling Li, PhD is VP, Biostatistics at Acrivon Therapeutics, Inc. Lingling is a highly accomplished drug development expert and statistical leader with a unique combination of experience in clinical development strategy, clinical study design, statistical methodology, analysis, regulatory matters (FDA, EMA), Good Clinical Practice (GCP) compliance, SOPs, and inspection readiness. Most recently, Lingling served as the VP of Biometrics for ImmunoGen overseeing a lean internal team to support the lead compound, Elahere®, a biomarker-driven ADC along with 3 other clinical-stage assets. Prior to that, at Karyopharm, Lingling had increasing roles and responsibilities and led the Biostatistics and Statistical Programming team in advancing 3 compounds across a variety of hematologic and solid tumor indications. Earlier in her career, Lingling worked at Sanofi, focusing on Pompe disease, following nearly a decade in academia as Assistant and Associate Professors at Harvard Medical School. Lingling received her PhD in Biostatistics from the Harvard T.H. Chan School of Public Health.